SCHEMBL6095884

SCHEMBL6095884

COC1=C(OC)C(=O)C(Cc2ccc(OC)c(C(=O)Nc3cccnc3Cl)c2)=C(C)C1=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.53
PDE4A P27815 1/20 0.52
PDE4B Q07343 1/20 0.52
PDE4C Q08493 1/20 0.52
PDE4D Q08499 1/20 0.52
KMT2A Q03164 5/20 0.49
RAB9A P51151 5/20 0.49
NPC1 O15118 4/20 0.49
MEN1 O00255 3/20 0.49
MAPT P10636 2/20 0.47
TP53 P04637 1/20 0.47
ALOX12 P18054 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095715 0.93 PDE4A (0.49) POLBPDE4APDE4BPDE4CPDE4D
SCHEMBL6094169 0.91 POLB (0.45) POLBPDE4APDE4BPDE4CPDE4D
SCHEMBL6095804 0.89 PDE4A (0.47) POLBPDE4APDE4BPDE4CPDE4D
SCHEMBL6095967 0.88 PDE4A (0.49) POLBPDE4APDE4BPDE4CPDE4D
SCHEMBL6095010 0.84 PDE4A (0.47) POLBPDE4APDE4BPDE4CPDE4D
SCHEMBL6094733 0.83 ALDH1A1 (0.40) POLBPDE4APDE4BPDE4CPDE4D
SCHEMBL6095856 0.81 POLB (0.47) POLBPDE4APDE4BPDE4CPDE4D
SCHEMBL6096656 0.81 KDM4E (0.38) POLBPDE4APDE4BPDE4CPDE4D
SCHEMBL6096733 0.80 ALDH1A1 (0.43) KMT2ARAB9ANPC1MEN1MAPT
SCHEMBL6095441 0.79 MEN1 (0.52) POLBKMT2ARAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064124-B2 NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-06-20 US claimed
US-7064124-B2 NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-06-20 US disclosed
US-20040122244-A1 Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2004-06-24 US disclosed
EP-1314712-A1 NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT Daiichi Suntory Pharma Co., Ltd. (JP) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122244-A1 Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient NFKBIA, NFKB1, IKBKB POLB 294/4885PDE4A 4132/4885PDE4B 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.